BACKGROUND: Chronic back pain is one of the costliest and most complex medical conditions to manage, involving physiological, psychological, mechanical, social, and environmental factors. An increasing trend of lumbar fusion (LF) surgery for chronic back pain continues despite conflicting evidence for pain relief or improved long-term outcomes. Our goal was to assess medical and pharmacy utilization (including continued use of pain medication) over a 2-year period among patients receiving LF to relieve back pain for degenerative conditions without instability. METHODS: We conducted a 2-year longitudinal cohort study of 1,422 commercially insured patients who received LF from January through September 2009, and who had continuous benefit eligibility through 2011. We assessed resource use among patients with ICD-9-CM diagnostic codes consistent with a degenerative condition, identified from Cigna's national claim database (CPT codes 22612, 22630 and/or 22558). Patients with fracture, tumor, infection, spondylolisthesis, inflammatory arthritis, or deformity diagnostic codes were excluded. RESULTS: Over the 2 years following LF, 992 patients (70%) incurred $9.0 million in additional medical claims payments which averaged $9,383 per patient. These payments included pain management interventions and long term therapy services in 30% of patients. A subset of 850 patients (60%) also had pharmacy benefits and 829 (97.5%) received multiple pain-related classes of medication over the same period. The majority of patients continued on chronic narcotic use (62.5%), and 95% of patients on narcotics preoperatively continued narcotic utilization at two years. This pharmacy benefit subset incurred an additional $2.2 million for pain-related medications at an average cost of $2,600 per patient. Total average payment for patients with combined medical and pharmacy benefits was $12,283. CONCLUSIONS: LF for patients with a degenerative lumbar diagnosis incurred significant resources postoperatively, and was followed by long-term pain and psychotropic medication utilization.
BACKGROUND:Chronic back pain is one of the costliest and most complex medical conditions to manage, involving physiological, psychological, mechanical, social, and environmental factors. An increasing trend of lumbar fusion (LF) surgery for chronic back pain continues despite conflicting evidence for pain relief or improved long-term outcomes. Our goal was to assess medical and pharmacy utilization (including continued use of pain medication) over a 2-year period among patients receiving LF to relieve back pain for degenerative conditions without instability. METHODS: We conducted a 2-year longitudinal cohort study of 1,422 commercially insured patients who received LF from January through September 2009, and who had continuous benefit eligibility through 2011. We assessed resource use among patients with ICD-9-CM diagnostic codes consistent with a degenerative condition, identified from Cigna's national claim database (CPT codes 22612, 22630 and/or 22558). Patients with fracture, tumor, infection, spondylolisthesis, inflammatory arthritis, or deformity diagnostic codes were excluded. RESULTS: Over the 2 years following LF, 992 patients (70%) incurred $9.0 million in additional medical claims payments which averaged $9,383 per patient. These payments included pain management interventions and long term therapy services in 30% of patients. A subset of 850 patients (60%) also had pharmacy benefits and 829 (97.5%) received multiple pain-related classes of medication over the same period. The majority of patients continued on chronic narcotic use (62.5%), and 95% of patients on narcotics preoperatively continued narcotic utilization at two years. This pharmacy benefit subset incurred an additional $2.2 million for pain-related medications at an average cost of $2,600 per patient. Total average payment for patients with combined medical and pharmacy benefits was $12,283. CONCLUSIONS: LF for patients with a degenerative lumbar diagnosis incurred significant resources postoperatively, and was followed by long-term pain and psychotropic medication utilization.
Authors: Richard A Deyo; Darryl T Gray; William Kreuter; Sohail Mirza; Brook I Martin Journal: Spine (Phila Pa 1976) Date: 2005-06-15 Impact factor: 3.468
Authors: Jens Ivar Brox; Roger Sørensen; Astrid Friis; Øystein Nygaard; Aage Indahl; Anne Keller; Tor Ingebrigtsen; Hege R Eriksen; Inger Holm; Anne Kathrine Koller; Rolf Riise; Olav Reikerås Journal: Spine (Phila Pa 1976) Date: 2003-09-01 Impact factor: 3.468
Authors: Brook I Martin; Richard A Deyo; Sohail K Mirza; Judith A Turner; Bryan A Comstock; William Hollingworth; Sean D Sullivan Journal: JAMA Date: 2008-02-13 Impact factor: 56.272
Authors: Mark D Sullivan; Mark J Edlund; Ming-Yu Fan; Andrea DeVries; Jennifer Brennan Braden; Bradley C Martin Journal: Pain Date: 2008-06-10 Impact factor: 6.961
Authors: Michael L Kent; Robert W Hurley; Gary M Oderda; Debra B Gordon; Eric Sun; Monty Mythen; Timothy E Miller; Andrew D Shaw; Tong J Gan; Julie K M Thacker; Matthew D McEvoy Journal: Anesth Analg Date: 2019-08 Impact factor: 5.108
Authors: Jeffrey S Fischgrund; Alfred Rhyne; Jörg Franke; Rick Sasso; Scott Kitchel; Hyun Bae; Christopher Yeung; Eeric Truumees; Michael Schaufele; Philip Yuan; Peter Vajkoczy; Michael Depalma; David G Anderson; Lee Thibodeau; Bernhard Meyer Journal: Int J Spine Surg Date: 2019-04-30
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Nicole O'Kane; Jody Carson; Joshua Van Otterloo; Dagan A Wright; Lisa M Millet; Wayne Wakeland Journal: Pain Date: 2018-06 Impact factor: 7.926
Authors: Sem M M Hermans; Aniek A G Lantinga-Zee; Kim Rijkers; Henk van Santbrink; Wouter L W van Hemert; Mattheus K Reinders; Daisy M N Hoofwijk; Sander M J van Kuijk; Inez Curfs Journal: Brain Spine Date: 2021-11-12